Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

Activation of the Amino Acid Response Pathway Blunts the Effects of Cardiac Stress.

Qin P, Arabacilar P, Bernard RE, Bao W, Olzinski AR, Guo Y, Lal H, Eisennagel SH, Platchek MC, Xie W, Del Rosario J, Nayal M, Lu Q, Roethke T, Schnackenberg CG, Wright F, Quaile MP, Halsey WS, Hughes AM, Sathe GM, Livi GP, Kirkpatrick RB, Qu XA, Rajpal DK, Faelth Savitski M, Bantscheff M, Joberty G, Bergamini G, Force TL, Gatto GJ Jr, Hu E, Willette RN.

J Am Heart Assoc. 2017 May 9;6(5). pii: e004453. doi: 10.1161/JAHA.116.004453.

2.

Orai and TRPC channel characterization in FcεRI-mediated calcium signaling and mediator secretion in human mast cells.

Wajdner HE, Farrington J, Barnard C, Peachell PT, Schnackenberg CG, Marino JP Jr, Xu X, Affleck K, Begg M, Seward EP.

Physiol Rep. 2017 Mar;5(5). pii: e13166. doi: 10.14814/phy2.13166.

3.

Combined TRPC3 and TRPC6 blockade by selective small-molecule or genetic deletion inhibits pathological cardiac hypertrophy.

Seo K, Rainer PP, Shalkey Hahn V, Lee DI, Jo SH, Andersen A, Liu T, Xu X, Willette RN, Lepore JJ, Marino JP Jr, Birnbaumer L, Schnackenberg CG, Kass DA.

Proc Natl Acad Sci U S A. 2014 Jan 28;111(4):1551-6. doi: 10.1073/pnas.1308963111. Epub 2014 Jan 22. Erratum in: Proc Natl Acad Sci U S A. 2014 Apr 22;111(16):6115.

4.

The discovery of potent blockers of the canonical transient receptor channels, TRPC3 and TRPC6, based on an anilino-thiazole pharmacophore.

Washburn DG, Holt DA, Dodson J, McAtee JJ, Terrell LR, Barton L, Manns S, Waszkiewicz A, Pritchard C, Gillie DJ, Morrow DM, Davenport EA, Lozinskaya IM, Guss J, Basilla JB, Negron LK, Klein M, Willette RN, Fries RE, Jensen TC, Xu X, Schnackenberg CG, Marino JP Jr.

Bioorg Med Chem Lett. 2013 Sep 1;23(17):4979-84. doi: 10.1016/j.bmcl.2013.06.047. Epub 2013 Jun 26.

PMID:
23886683
5.

Discovery of 1-(1,3,5-triazin-2-yl)piperidine-4-carboxamides as inhibitors of soluble epoxide hydrolase.

Thalji RK, McAtee JJ, Belyanskaya S, Brandt M, Brown GD, Costell MH, Ding Y, Dodson JW, Eisennagel SH, Fries RE, Gross JW, Harpel MR, Holt DA, Israel DI, Jolivette LJ, Krosky D, Li H, Lu Q, Mandichak T, Roethke T, Schnackenberg CG, Schwartz B, Shewchuk LM, Xie W, Behm DJ, Douglas SA, Shaw AL, Marino JP Jr.

Bioorg Med Chem Lett. 2013 Jun 15;23(12):3584-8. doi: 10.1016/j.bmcl.2013.04.019. Epub 2013 Apr 16.

PMID:
23664879
6.

Chronic inhibition of 11 β -hydroxysteroid dehydrogenase type 1 activity decreases hypertension, insulin resistance, and hypertriglyceridemia in metabolic syndrome.

Schnackenberg CG, Costell MH, Krosky DJ, Cui J, Wu CW, Hong VS, Harpel MR, Willette RN, Yue TL.

Biomed Res Int. 2013;2013:427640. doi: 10.1155/2013/427640. Epub 2013 Mar 18.

7.

An orally active TRPV4 channel blocker prevents and resolves pulmonary edema induced by heart failure.

Thorneloe KS, Cheung M, Bao W, Alsaid H, Lenhard S, Jian MY, Costell M, Maniscalco-Hauk K, Krawiec JA, Olzinski A, Gordon E, Lozinskaya I, Elefante L, Qin P, Matasic DS, James C, Tunstead J, Donovan B, Kallal L, Waszkiewicz A, Vaidya K, Davenport EA, Larkin J, Burgert M, Casillas LN, Marquis RW, Ye G, Eidam HS, Goodman KB, Toomey JR, Roethke TJ, Jucker BM, Schnackenberg CG, Townsley MI, Lepore JJ, Willette RN.

Sci Transl Med. 2012 Nov 7;4(159):159ra148. doi: 10.1126/scitranslmed.3004276.

8.

Comparison of soluble guanylate cyclase stimulators and activators in models of cardiovascular disease associated with oxidative stress.

Costell MH, Ancellin N, Bernard RE, Zhao S, Upson JJ, Morgan LA, Maniscalco K, Olzinski AR, Ballard VL, Herry K, Grondin P, Dodic N, Mirguet O, Bouillot A, Gellibert F, Coatney RW, Lepore JJ, Jucker BM, Jolivette LJ, Willette RN, Schnackenberg CG, Behm DJ.

Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012.

9.

Design and synthesis of orally bioavailable serum and glucocorticoid-regulated kinase 1 (SGK1) inhibitors.

Hammond M, Washburn DG, Hoang HT, Manns S, Frazee JS, Nakamura H, Patterson JR, Trizna W, Wu C, Azzarano LM, Nagilla R, Nord M, Trejo R, Head MS, Zhao B, Smallwood AM, Hightower K, Laping NJ, Schnackenberg CG, Thompson SK.

Bioorg Med Chem Lett. 2009 Aug 1;19(15):4441-5. doi: 10.1016/j.bmcl.2009.05.051. Epub 2009 May 18.

PMID:
19497745
10.

Development of a small-molecule serum- and glucocorticoid-regulated kinase-1 antagonist and its evaluation as a prostate cancer therapeutic.

Sherk AB, Frigo DE, Schnackenberg CG, Bray JD, Laping NJ, Trizna W, Hammond M, Patterson JR, Thompson SK, Kazmin D, Norris JD, McDonnell DP.

Cancer Res. 2008 Sep 15;68(18):7475-83. doi: 10.1158/0008-5472.CAN-08-1047.

11.

11beta-hydroxysteroid dehydrogenase type 1 inhibitors for metabolic syndrome.

Schnackenberg CG.

Curr Opin Investig Drugs. 2008 Mar;9(3):295-300. Review.

PMID:
18311666
12.

Crystal structure of the kinase domain of serum and glucocorticoid-regulated kinase 1 in complex with AMP PNP.

Zhao B, Lehr R, Smallwood AM, Ho TF, Maley K, Randall T, Head MS, Koretke KK, Schnackenberg CG.

Protein Sci. 2007 Dec;16(12):2761-9. Epub 2007 Oct 26.

13.

PPARdelta activation normalizes cardiac substrate metabolism and reduces right ventricular hypertrophy in congestive heart failure.

Jucker BM, Doe CP, Schnackenberg CG, Olzinski AR, Maniscalco K, Williams C, Hu TC, Lenhard SC, Costell M, Bernard R, Sarov-Blat L, Steplewski K, Willette RN.

J Cardiovasc Pharmacol. 2007 Jul;50(1):25-34.

PMID:
17666912
14.

The elevated blood pressure of human GRK4gamma A142V transgenic mice is not associated with increased ROS production.

Wang Z, Armando I, Asico LD, Escano C, Wang X, Lu Q, Felder RA, Schnackenberg CG, Sibley DR, Eisner GM, Jose PA.

Am J Physiol Heart Circ Physiol. 2007 May;292(5):H2083-92. Epub 2007 Jan 26.

16.

Effects of angiotensins II and IV on blood pressure, renal function, and PAI-1 expression in the heart and kidney of the rat.

Abrahamsen CT, Pullen MA, Schnackenberg CG, Grygielko ET, Edwards RM, Laping NJ, Brooks DP.

Pharmacology. 2002 Sep;66(1):26-30.

PMID:
12169762
17.

Oxygen radicals in cardiovascular-renal disease.

Schnackenberg CG.

Curr Opin Pharmacol. 2002 Apr;2(2):121-5. Review.

PMID:
11950621
18.

Physiological and pathophysiological roles of oxygen radicals in the renal microvasculature.

Schnackenberg CG.

Am J Physiol Regul Integr Comp Physiol. 2002 Feb;282(2):R335-42. Review.

19.
20.

Renal mechanisms of angiotensin II-induced hypertension.

Granger JP, Schnackenberg CG.

Semin Nephrol. 2000 Sep;20(5):417-25. Review.

PMID:
11022893
21.

TP receptor-mediated vasoconstriction in microperfused afferent arterioles: roles of O(2)(-) and NO.

Schnackenberg CG, Welch WJ, Wilcox CS.

Am J Physiol Renal Physiol. 2000 Aug;279(2):F302-8.

22.

Nitric oxide synthase in the JGA of the SHR: expression and role in tubuloglomerular feedback.

Welch WJ, Tojo A, Lee JU, Kang DG, Schnackenberg CG, Wilcox CS.

Am J Physiol. 1999 Jul;277(1):F130-8. doi: 10.1152/ajprenal.1999.277.1.F130.

PMID:
10409306
23.
24.
25.

Verapamil abolishes the preglomerular response to ANG II during intrarenal nitric oxide synthesis inhibition.

Schnackenberg CG, Granger JP.

Am J Physiol. 1997 May;272(5 Pt 2):R1670-6.

PMID:
9176363
26.

Inhibition of intrarenal NO stimulates renin secretion through a macula densa-mediated mechanism.

Schnackenberg CG, Tabor BL, Strong MH, Granger JP.

Am J Physiol. 1997 Mar;272(3 Pt 2):R879-86.

PMID:
9087651
27.

Supplemental Content

Loading ...
Support Center